====== Nisha Andany ======

{{ :nisha.png?150|}}

Dr. **Nisha Andany** is a member of the [[Ontario COVID-19 Science Advisory Table]].((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved December 23, 2021, from https://covid19-sciencetable.ca/about/#andany-nisha))

===== Education =====

Andany completed her Bachelor of Sciences at the [[University of Waterloo]] in 2007. She majored in health studies and biology. She then received her MD in 2011 from the [[University of Toronto]]. She completed a Masters in Public Health at the [[Harvard T.H. Chan School of Public Health]] in 2018.((Imrie, K. (2018). //A message from the Physician-in-Chief, Dr. Kevin Imrie.// Department of Medicine Fall Newsletter, 3. Sunnybrook Health Sciences Centre. https://sunnybrook.ca/uploads/1/departments/medicine/dom_180901.pdf))

===== Affiliations =====

==== Ontario COVID-19 Science Advisory Table ====

Andany is a member of the Drugs & Biologics Clinical Practice Guidelines Working Group on the [[Ontario COVID-19 Science Advisory Table]]. In this role, she co-authored a paper advocating against using [[ivermectin]] for prophylaxis or treatment of [[COVID-19]] on the grounds that “inappropriate use of ivermectin for COVID-19 may make it unavailable for patients who could benefit from its use (i.e., patients with serious parasitic infections) and reduce the already limited supply of ivermectin in Canada.”((Leung, E., McIntyre, M., Andany, N., Ciccotelli, W. A., Graham, C., Jüni, P., Langford, B., McCarthy, A. E., Nott, C., Gold, W. L., Pai, M., Patel, S., Raybardhan, S., Stall, N. M., & Morris, A. M. (2021). //Ivermectin to Prevent Disseminated Strongyloides Infection in Patients with COVID-19.// Science Briefs of the Ontario COVID-19 Science Advisory Table, 2(30). https://doi.org/10.47326/ocsat.2021.02.30.1.0)) 

Another paper bearing her name described [[azithromycin]], [[bamlanivimab]], [[colchicine]], [[hydroxychloroquine]], ivermectin, [[lopinavir-ritonavir]], and [[vitamin D]] as “non-recommended therapies” which “either have demonstrable harm or lack sufficient evidence from randomized trials to warrant their use.” They advocated instead for use of [[dexamethasone]], as well as [[monoclonal antibody]] treatments [[casirivimab]] and [[imdevimab]] (produced by [[Regeneron]]).((//Regeneron’s COVID-19 Response Efforts.// Regeneron. Retrieved December 24, 2021, from https://www.regeneron.com/covid19)) ((Morris, A. M., Andany, N., Bobos, P., Carlin, S., Ciccotelli, W., Graham, C. M., Kan, T., Langford, B. J., Leung, E., McElroy, R., Miller, K. J., Neil, U., Nott, C., Jüni, P., & Pai, M. (2021). //Evidence-Based Use of Therapeutics for Ambulatory Patients with COVID-19.// Science Briefs of the Ontario COVID-19 Science Advisory Table, 2(48). https://doi.org/10.47326/ocsat.2021.02.48.1.0))

==== Sunnybrook Health Sciences Centre ====

Andany is employed as an Infectious Diseases and HIV Specialist at [[Sunnybrook Health Sciences Centre]]. She works as Educational Lead, staff physician, and Affiliate Scientist, Evaluative Clinical Sciences, Integrated Community Program.((//Nisha Andany MD, MPH, FRCP(C).// Sunnybrook Research Institute. Retrieved December 23, 2021, from https://archive.ph/oELd1 )) She participated in the centre's [[COVIDEO]] telehealth program.((Millar, S. (2020, May 11). //Sunnybrook patients recovering at home from COVID-19 get advice, support from new virtual program.// Sunnybrook Research Institute. https://archive.ph/sN4y1)) ((Ogilvie, M. (2021, January 25). //Canada’s first COVID-19 patient was at Sunnybrook. Today his treatment would have been by video.// The Toronto Star. https://www.thestar.com/news/gta/2021/01/25/canadas-first-covid-19-patient-was-at-sunnybrook-today-his-treatment-would-have-been-by-video.html))

Her relevant publications include:

  * [[https://www.campfire.wiki/lib/exe/fetch.php?media=s12913-021-06602-1.pdf|June 30, 2021]]: //Patient perspectives on the implementation of routinised syphilis screening with HIV viral load testing: Qualitative process evaluation of the Enhanced Syphilis Screening Among HIV-positive Men trial.//((MacKinnon, K. R., Grewal, R., Tan, D. H., Rousseau, R., Maxwell, J., Walmsley, S., MacPherson, P. A., Rachlis, A., Andany, N., Mishra, S., Allen, V. G., & Burchell, A. N. (2021). //Patient perspectives on the implementation of routinised syphilis screening with HIV viral load testing: Qualitative process evaluation of the Enhanced Syphilis Screening Among HIV-positive Men trial.// BMC Health Services Research, 21(1). https://doi.org/10.1186/s12913-021-06602-1)) Funded by a Canadian Institutes of Health Research (CIHR) Foundation award, the CIHR Canadian HIV Trials Network, a CIHR New Investigator Salary Award, Ontario HIV Treatment Network Endgame Leader Award, and a Non-Clinician Researcher award from the Department of Family and Community Medicine, Faculty of Medicine, University of Toronto.

  * [[https://www.campfire.wiki/lib/exe/fetch.php?media=e046282.full.pdf|March 8, 2021]]: //Diagnostic accuracy of subjective dyspnoea in detecting hypoxaemia among outpatients with COVID-19: a retrospective cohort study.//((Berezin, L., Zhabokritsky, A., Andany, N., Chan, A. K., Estrada-Codecido, J., Gershon, A., Lam, P. W., Leis, J. A., MacPhee, S., Mubareka, S., Simor, A. E., & Daneman, N. (2021). //Diagnostic accuracy of subjective dyspnoea in detecting hypoxaemia among outpatients with COVID-19: a retrospective cohort study.// BMJ Open, 11(3), e046282. https://doi.org/10.1136/bmjopen-2020-046282))

  * [[https://www.campfire.wiki/lib/exe/fetch.php?media=wiki:e1306.full.pdf|October 2020]]: //Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy//. Andany discloses funding from [[Janssen]], [[gsk|GlaxoSmithKline]] and [[Gilead Sciences]] for other HIV research.((Halani, S., Andany, N., & Shah, R. (2020). //Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy.// Canadian Medical Association Journal, 192(43), E1306–E1308. https://doi.org/10.1503/cmaj.200846))

  * [[https://www.campfire.wiki/lib/exe/fetch.php?media=piis0012369220316524.pdf|September 1, 2020]]: //Home or Cabin: Community Care for Coronavirus Disease 2019//((Andany, N., & Daneman, N. (2020). //Home or Cabin: Community Care for Coronavirus Disease 2019.// Chest, 158(3), 839–840. https://doi.org/10.1016/j.chest.2020.06.002))

  * [[https://www.campfire.wiki/lib/exe/fetch.php?media=e407.full.pdf|May 23, 2020]]: //A virtual care program for outpatients diagnosed with COVID-19: a feasibility study//((Lam, P. W., Sehgal, P., Andany, N., Mubareka, S., Simor, A. E., Ozaldin, O., Leis, J. A., Daneman, N., & Chan, A. K. (2020). //A virtual care program for outpatients diagnosed with COVID-19: a feasibility study.// CMAJ Open, 8(2), E407–E413. https://doi.org/10.9778/cmajo.20200069))
 
  * [[https://journals.lww.com/menopausejournal/Abstract/2020/01000/Prevalence_and_correlates_of_early_onset_menopause.11.aspx|January 2020]]: //Prevalence and correlates of early-onset menopause among women living with HIV in Canada//.((Andany, N., Kaida, A., de Pokomandy, A., Yudin, M. H., Wang, L., Kennedy, V. L., Webster, K., & Loutfy, M. (2019). //Prevalence and correlates of early-onset menopause among women living with HIV in Canada.// Menopause, 27(1), 66–75. https://doi.org/10.1097/gme.0000000000001423)) Funded by the [[Canadian Institutes of Health Research]] (CIHR), [[Canadian Institutes of Health Research:CIHR Canadian HIV Trials Network]], [[Ontario HIV Treatment Network]], the [[Academic Health Science Centres Alternative Funding Plans (AFP) Innovation Fund]], and [[Fonds de Recherche du Québec—Santé]]. Presented at the 7th International Workshop on HIV and Women in Seattle, Washington (February 11-12, 2017), funded by [[Gilead Sciences]].((//SUPPORT.// Virology Education. Retrieved December 23, 2021, from https://archive.ph/I7XYf)) Also presented at the [[Conference on Retroviruses and Opportunistic Infections]] (February 13-16) in Seattle, funded by [[Merck]], [[ViiV Healthcare]], [[AbbVie]], [[Hologic]] and [[Cepheid]].((//Funding Information.// CROI Conference. Retrieved December 23, 2021, from https://www.croiconference.org/about/commercial-support/))

  * //Association between initial symptoms and subsequent hospitalization in outpatients with COVID-19: A cohort study.//(( Zhabokritsky, A., Daneman, N., MacPhee, S., Estrada-Codecido, J., Santoro, A., Kit Chan, A., Wai-Hei Lam, P., Simor, A., Allen Leis, J., Mubareka, S., & Andany, N. (2021). //Association between initial symptoms and subsequent hospitalization in outpatients with COVID-19: A cohort study.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 6(4), 259–268. https://doi.org/10.3138/jammi-2021-0012)) Funded by the [[Sunnybrook COVID-19 Research Initiative]].

==== University of Toronto ====

Adany is employed as Assistant Professor in the Department of Medicine at the [[University of Toronto]].((//Nisha Andany.// (2021). University of Toronto. https://facdir.deptmedicine.utoronto.ca/Detail.aspx?id=2830&showdivisiontitle=1&division_id=I03))

===== Relationships with Pharmaceutical Companies =====

Andany has received funding for [[HIV]] research from [[Janssen]], [[GlaxoSmithKline]] and [[Gilead Sciences]].((Andany, N. (2021, August 23). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Nisha-Andany_20210823.pdf)) ((Andany, N. (2021, May 25). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Nisha-Andany_20210525.pdf)) ((Andany, N. (2021, February 8). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Nisha-Andany.pdf))